Recombinant Human PLA2G4A Protein, CF

Catalog #: 6659-PL Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
6659-PL-010

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human PLA2G4A Protein, CF Summary

Product Specifications

Purity

>80%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to hydrolyze 1-Hexadecanoyl-2-(1-pyrene-decanoyl)-sn-glycero-3-phosphocholine. The specific activity is >15 pmol/min/μg, as measured under the described conditions.

Source

Spodoptera frugiperda, Sf 21 (baculovirus)-derived human PLA2G4A protein
Met1-Ala749, with a C-terminal 6-His tag

Accession #

NP_077734

N-terminal Sequence
Analysis

Ser2

Predicted Molecular Mass

86 kDa

SDS-PAGE

85-95 kDa, reducing conditions

Product Datasheets

6659-PL

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

6659-PL

Formulation	Supplied as a 0.2 μm filtered solution in Tris, NaCl, TCEP,Brij-35 and Glycerol.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 3 months, -20 to -70 °C under sterile conditions after opening.

Assay Procedure

Materials

Assay Buffer: 50 mM Tris, 500 mM NaCl, 1 mg/mL BSA, pH 8.5
Substrate Buffer: 50 mM Tris, 500 mM NaCl, 20 mM CaCl₂, 1 mg/mL BSA, pH 8.5
Recombinant Human PLA2G4A (rhPLA2G4A) (Catalog # 6659-PL)
Substrate: 1-Hexadecanoyl-2-(1-Pyrenedecanoyl)-sn-Glycero-3-Phosphocholine (Invitrogen, Catalog # H361), Dilute to 2 mM in DMSO, then dilute to a final stock concentration of 400 µM in ethanol
F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent

Thaw Substrate at 37 °C for five minutes. Mix well.
Dilute rhPLA2G4A to 2 µg/mL in Assay Buffer.
Dilute Substrate to 10 µM in Substrate Buffer.
Load 50 µL of 2 µg/mL rhPLA2G4A into a black well plate, and start the reaction by adding 50 µL of 10 µM Substrate. Include a Substrate Blank containing 50 µL of Assay Buffer and 50 µL of 10 µM Substrate.
Read at excitation and emission wavelengths of 345 nm and 395 nm (top read), respectively, in kinetic mode for 5 minutes.
Calculate specific activity:

Specific Activity (pmol/min/µg) =	Adjusted V_max* (RFU/min) x Conversion Factor** (pmol/RFU)
	amount of enzyme (µg)

*Adjusted for Substrate Blank
**Derived using calibration standard 1-pyrenedecanoic acid (Invitrogen, Catalog # P31).

Per Well:

rhPLA2G4A: 0.10 µg
Substrate: 5 µM

Reconstitution Calculator

Background: PLA2G4A

Cytosolic Phospholipase A2a (PLA2G4A) belongs to the group IV phospholipase A2 family (1). These enzymes hydrolyze the ester bond at the second position (sn-2) of membrane glycerophospholipids. The group IV phospholipase A2 (PLA2G4) family is comprised of six intracellular enzymes (2). PLA2G4A has a preference for arachidonic acid in the sn-2 position of phospholipids indicating its involvement in the metabolism of eicosanoids. Its active site is characterized by a serine and aspartic acid dyad. The overall structural feature displays two domains, a lipid binding C2 domain and a catalytic a/b hydrolase domain. PLA2G4A translocation to the membrane and activation is facilitated by a calcium‑ion dependent conformational change in its C2 domain. In addition, phosphorylation of serine residues in PLA2G4A by protein kinases may be another regulatory mechanism for promoting the release of arachidonic acid. The knockout mouse studies of this enzyme indicate that the enzyme may play a major role in inflammatory diseases. Genetic ablation or reduction of PLA2G4A protected human amyloid precursor protein (APP) related pathogenesis from a mouse model (3). Mouse model studies of brain and lung cancer indicates that PLA2G4A may play a key regulatory role in angiogenesis of these tumors (4).

References

Burke, J. E. and E.A. Dennis (2009) J. Lipid Res. 50:S237.
Ghosh, M. et al. (2006) Prog. Lipid Res. 45:487.
Sanchez-Mejia, R.O. et al. (2008) Nat. Neuroscience 11:1311.
Linkous, A.G. et al. (2010) J. Natl. Cancer Inst. 102:1398.

Long Name

Phospholipase A2 Group IV A

Entrez Gene IDs

5321 (Human); 18783 (Mouse); 24653 (Rat)

Alternate Names

calcium-dependent phospholipid-binding protein; cPLA2; cPLA2-alpha; lysophospholipase; MGC126350; phosphatidylcholine 2-acylhydrolase; Phospholipase A2 group IVA; phospholipase A2, group IVA (cytosolic, calcium-dependent); PLA2G4A; PLA2G4cytosolic phospholipase A2